Named Bioactive Compounds · Compound
Vasicine
Moderate Evidencecompound
Hermetica Superfood Encyclopedia
Vasicine is a quinazoline alkaloid primarily derived from Adhatoda vasica that functions as an acetylcholinesterase inhibitor. This compound shows preliminary evidence for cognitive support and anti-inflammatory effects through cholinergic pathway modulation.
Vasicine is a quinazoline alkaloid primarily isolated from Justicia adhatoda (Adhatoda vasica), a medicinal shrub in the Acanthaceae family native to India. It is extracted from leaves or roots using solvent extraction methods documented since the late 19th century, and is also found in Peganum harmala and Sida cordifolia.
No human clinical trials, RCTs, or meta-analyses specifically on vasicine were identified. Evidence is limited to preclinical in vitro and animal studies, with semi-synthetic derivatives like bromhexine and ambroxol showing some activity but no vasicine-specific human data with PMIDs available.
No clinically studied dosage ranges for vasicine have been established due to absence of human trials. Studies on Adhatoda vasica extracts do not specify standardization percentages or dosages used. Consult a healthcare provider before starting any new supplement.
Vasicine (also known as peganine) is a quinazoline alkaloid (molecular formula C₁₁H₁₂N₂O, molecular weight ~188.23 g/mol) and is not a nutrient or food source; therefore, standard macronutrient/micronutrient profiling does not apply. Key biochemical and bioactive characteristics include: • Primary bioactive identity: 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol; a pyrroloquinazoline alkaloid isolated primarily from Adhatoda vasica (Malabar nut) leaves, where it occurs at concentrations of approximately 0.5–1.5% dry weight of leaf material. Also found in lower concentrations in Peganum harmala seeds (~0.25–0.5% dry weight). • Key related compounds: Vasicinone (its auto-oxidation product and pharmacologically active metabolite), vasicinol, and deoxyvasicine are frequently co-extracted. The vasicine-to-vasicinone ratio in plant material varies with harvest time and processing (fresh leaves tend toward higher vasicine; dried/aged material shifts toward vasicinone). • Bioavailability notes: Vasicine is water-soluble and shows moderate oral bioavailability in animal pharmacokinetic studies (estimated ~30–50% in rodent models). It undergoes hepatic oxidative metabolism, converting partly to vasicinone (via CYP450-mediated oxidation), which retains and in some cases enhances bronchodilatory activity. The compound crosses the blood-brain barrier to some extent, consistent with its observed acetylcholinesterase inhibitory effects in CNS tissue models. Peak plasma concentrations in rodent studies are reached within 1–2 hours post-oral administration. • Additional bioactive properties relevant to its profile: Acts as a competitive, reversible acetylcholinesterase (AChE) inhibitor with IC₅₀ values reported in the range of ~50–150 µM (in vitro, depending on assay conditions and enzyme source). Exhibits uterotonic (oxytocic) activity. Demonstrates mucolytic and bronchodilatory effects (historically the primary traditional use of Adhatoda vasica). • No vitamins, minerals, fiber, or protein content — vasicine is a single purified alkaloid compound, not a whole food or dietary supplement matrix. • Safety note: As an alkaloid with pharmacological activity (particularly uterotonic effects), vasicine is not consumed as a nutritional agent and has no established dietary reference intake. Therapeutic or experimental doses in animal studies typically range from 5–50 mg/kg body weight orally.
Vasicine inhibits acetylcholinesterase enzyme activity, preventing the breakdown of acetylcholine and enhancing cholinergic neurotransmission. The compound also demonstrates anti-inflammatory effects by modulating inflammatory mediator release in carrageenan-induced inflammation models. Its quinazoline structure contributes to potential anti-cancer activity through structure-activity relationships affecting cellular proliferation pathways.
Current evidence for vasicine is limited to in vitro and animal studies with no human clinical trials available. In vitro neuroblastoma cell studies demonstrate acetylcholinesterase inhibition, suggesting potential cognitive benefits. Animal studies using carrageenan-induced inflammation models show anti-inflammatory effects, but specific dosages and effect magnitudes are not well-established. The preliminary nature of available research limits definitive conclusions about therapeutic efficacy in humans.
Safety data for vasicine supplementation in humans is extremely limited due to lack of clinical trials. As an acetylcholinesterase inhibitor, vasicine may potentially interact with cholinergic medications and could theoretically enhance effects of other acetylcholinesterase inhibitors. Pregnancy and lactation safety has not been established. Individuals with neurological conditions or those taking medications affecting acetylcholine levels should exercise caution.
